Have a personal or library account? Click to login
Life-Time Risk, Screening and The Cost of Cardiovascular Comorbidities in CKD Patients Cover

Life-Time Risk, Screening and The Cost of Cardiovascular Comorbidities in CKD Patients

PRILOZI
Volume 36 (2015): Issue 2 (December 2015)
By: Carmine Zoccali,  Samar Abd ElHafeez,  Evangelia Dounousi,  Rossana Anastasi,  Giovanni Tripepi and  Francesca Mallamaci  
Open Access
|Dec 2015

References

  1. 1. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis. 2009; 53: S4-16.10.1053/j.ajkd.2008.07.048
    Search in Google Scholar
  2. 2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266.
    Search in Google Scholar
  3. 3. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008; 8: 117.10.1186/1471-2458-8-117
    Search in Google Scholar
  4. 4. Tonelli M, Riella M. Chronic kidney disease and the ageing population. Lancet. 2014; 383: 1278-1279.10.1016/S0140-6736(14)60155-0
    Search in Google Scholar
  5. 5. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382: 339-352.10.1016/S0140-6736(13)60595-4
    Search in Google Scholar
  6. 6. Grams ME, Juraschek SP, Selvin E et al. Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates. Am J Kidney Dis. 2013; 62: 253-260.10.1053/j.ajkd.2013.03.013
    Search in Google Scholar
  7. 7. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant. 2002; 17 Suppl 11: 50-54.10.1093/ndt/17.suppl_11.50
    Search in Google Scholar
  8. 8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.10.1161/circ.106.25.3143
    Search in Google Scholar
  9. 9. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012; 380: 807-814.10.1016/S0140-6736(12)60572-8
    Search in Google Scholar
  10. 10. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129: S1-45.
    Search in Google Scholar
  11. 11. Grams ME, Chow EK, Segev DL, Coresh J. Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis. 2013; 62: 245-252.10.1053/j.ajkd.2013.03.009372371123566637
    Search in Google Scholar
  12. 12. Hoerger TJ, Wittenborn JS, Segel JE et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010; 55: 463-473.10.1053/j.ajkd.2009.11.01720116910
    Search in Google Scholar
  13. 13. Fink HA, Ishani A, Taylor BC et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012; 156: 570-581.10.7326/0003-4819-156-8-201204170-0000822508735
    Search in Google Scholar
  14. 14. Qaseem A, Hopkins RH, Jr., Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159: 835-847.10.7326/0003-4819-159-11-201312030-0000924297193
    Search in Google Scholar
  15. 15. Hill NR, Lasserson D, Fatoba S et al. The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open. 2013; 3: e004265.10.1136/bmjopen-2013-004265388462424345903
    Search in Google Scholar
  16. 16. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006; 27: 1245-1250.10.1093/eurheartj/ehi88016611670
    Search in Google Scholar
  17. 17. Reinhold T, Lindig C, Willich SN, Bruggenjurgen B. The costs of myocardial infarction - a longitudinal analysis using data from a large German health insurance company. J Public Health 19, 579-586. 2011.10.1007/s10389-011-0420-8
    Search in Google Scholar
  18. 18. Icks A, Haastert B, Gandjour A et al. Costs of dialysis-- a regional population-based analysis. Nephrol Dial Transplant. 2010; 25: 1647-1652.10.1093/ndt/gfp67220008830
    Search in Google Scholar
  19. 19.http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/File:Gross_domestic_product_at_market_prices_2011.png. Eurostat. 2014.
    Search in Google Scholar
DOI: https://doi.org/10.1515/prilozi-2015-0056 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Journal RSS Feed
Language: English
Page range: 85 - 90
Published on: Dec 30, 2015
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Chronic Kidney Disease (CKD),
cardiovascular comorbidities,
life-time risk
Related subjects:
Medicine,
Basic medical science,
History and ethics of medicine,
Clinical medicine,
Clinical medicine, other,
Social sciences,
Education,
Education, other

© 2015 Carmine Zoccali, Samar Abd ElHafeez, Evangelia Dounousi, Rossana Anastasi, Giovanni Tripepi, Francesca Mallamaci, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 36 (2015): Issue 2 (December 2015)Next article